Last reviewed · How we verify
MT-8554
At a glance
| Generic name | MT-8554 |
|---|---|
| Also known as | Elismetrep |
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women (PHASE2)
- Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms (PHASE2)
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms (PHASE1)
- A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects (PHASE1)
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects (PHASE1)
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects (PHASE1)
- Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy (PHASE2)
- Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-8554 CI brief — competitive landscape report
- MT-8554 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI